

MALAWI Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Malawi						
2. Grant number: 17-MWI-12c-X / 17-MWI-25a-Y						
3. Date of Decision Letter: 28 February 2017						
4. Date of the Partnership Framework Agreement: 29 October 2013						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID, Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID ¹						
8. Programme duration²: 2011 - 2020						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2011-2016	2017	2018	2019	2020	Total ³
Programme Budget (US\$)	US\$56,129,842 ⁴	US\$9,017,500	7,636,000	8,176,000	8,713,500	US\$89,672,842
10. Vaccine introduction grant (in US\$): Country qualifies for a product switch grant of up to US\$ 182,500 to support the PCV switch. The funding will be transferred upon submission and approval of the budget for utilisation of the product switch grant.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵						
Type of supplies to be purchased with Gavi funds in each year	2011-2016	2017				
Number of Pneumococcal vaccines doses		2,402,000				
Annual Amounts (US\$)	US\$56,129,842 ⁶		US\$9,017,500			

¹ Country requested a switch to PCV13, 4 dose vial, in 2017. The timing of the first shipments of PCV13, 4 dose vial, will be determined during the development of the 2017 shipment plan based on your desired timing, the stock of the existing presentation of PCV, supply availability, and programmatic readiness to switch. Wastage has been estimated at 10% to align with WHO indicative wastage for the PCV13 4 dose vial and co-financing is aligned with your desired presentation in anticipation of the switch.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

⁶ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
13. Self-procurement: Not applicable	
14. Co-financing obligations: Reference code: 17-MWI-12c-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	147,500
Value of vaccine doses (US\$)	US\$486,745
Total co-financing payments (US\$) (including freight)	US\$510,000
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions: Not applicable	

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2017